ACROSS Global launched its first edition of the “CAR T-Cell Therapy Paper”

6-June-2019:

ACROSS Global launched its first edition of the “CAR T-Cell Therapy Paper”. A bi-annual, open-access online paper covering CAR T-Cell Therapy. The journal covers a broad range of CAR T-Cell topics compiled from a variety of publicly available sources.

The journal presents the reader with up-to-date news, NDA approvals, data trends, changes in global regulations, as well as company profiles and pipelines in what is a rapidly growing therapy area. The journal also provides a regional overview of the latest clinical trial statistics as well as featuring a spotlight on companies engaged in emerging CAR T-Cell technologies.

 

About ACROSS Global:

ACROSS Global is a strategic alliance of CROs and specialist vendors comprising 1,600+ employees. Multiple members provide access to 95 countries, 85% of the world’s population, and ~7,500 study sites. ACROSS delivers high quality, cost-effective global clinical trials. Local knowledge, globally experienced professionals and the latest technology allows ACROSS to deliver seamless global studies.

 

For further information please contact:

Steven Bukvic: Chairman, Exec. Committee. ACROSS Global Alliance bukvics@across.global